Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial
出版年份 2015 全文链接
标题
Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial
作者
关键词
-
出版物
Journal of Diabetes
Volume 8, Issue 2, Pages 229-237
出版商
Wiley
发表日期
2015-03-06
DOI
10.1111/1753-0407.12284
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1
- (2015) Markku Laakso et al. DIABETES CARE
- Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis
- (2014) Zhengpei Zeng et al. CURRENT MEDICAL RESEARCH AND OPINION
- Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States
- (2013) Ronald C.W. Ma et al. Annals of the New York Academy of Sciences
- Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial
- (2013) Zhengpei Zeng et al. CURRENT MEDICAL RESEARCH AND OPINION
- Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin
- (2012) Ulrike Graefe-Mody et al. CLINICAL PHARMACOKINETICS
- Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study
- (2012) J. B. McGill et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus
- (2012) C. Pan et al. DIABETES OBESITY & METABOLISM
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*†
- (2012) Wenying YANG et al. Journal of Diabetes
- Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2011) R. Gomis et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial
- (2011) Wenying Yang et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1
- (2011) D. R. Owens et al. DIABETIC MEDICINE
- Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2010) M.-R. Taskinen et al. DIABETES OBESITY & METABOLISM
- Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
- (2010) S. Del Prato et al. DIABETES OBESITY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started